A.L. Moreno Vega

Hospital Universitario Virgen del Rocío

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Edurne Arriola

Hospital Del Mar

M.J. Flor

Hospital Universitario Virgen del Rocío

Irene Carrasco García

Hospital Universitario Virgen del Rocío

L. Fernández

University of Technology Sydney

Sebastián Díaz

Hospital Universitario de Valme

G. Martínez Bernal

Hospital Universitario Virgen del Rocío

P. Sancho Marquez

Hospital Universitario Virgen del Rocío

Margarita Majem

Hospital de Sant Pau

Carlos Aguado

Hospital Clínico San Carlos

ÁC

Á. Callejo Mellén

AstraZeneca (Spain)

Cooperative Institutions

Hospital de Sant Pau

Instituto de Salud Carlos III

Centro de Investigación Biomédica en Red de Cáncer

Hospital Universitario Virgen del Rocío

Universitat Autònoma de Barcelona

Institut de Recerca Sant Pau

Hospital Universitario 12 De Octubre

Universidad Complutense de Madrid

Centro de Investigación Biomédica en Red

University of Córdoba

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

76P Leiomyosarcoma: Reviewing first-line options

ESMO Open (2024)

L. Fernández Irene Carrasco García Sebastián Díaz G. Martínez Bernal P. Sancho Marquez

Leiomyosarcomas are one of the most common types of sarcomas, with an estimated incidence between 10 and 20% of all sarcomas. Unfortunately, despite optimal locoregional treatments, leiomyosarcoma may relapse. At the European level through EORTC, efforts were made to assess different regimens in combination with doxorubicin for the treatment of metastatic unresectable leiomyosarcoma. A total of 71 patients treated between 2010-2023 were retrospectively selected, all of whom had provided consent for the use of their data. To obtain a more homogeneous sample, only those patients treated in the first line with anthracyclines in monotherapy or in combination, and gemcitabine and docetaxel were selected from the initially identified group. A total of 71 patients were retrospectively reviewed, comprising 62 women and 9 men. Age at diagnosis was 53 years (range: 26-86 years). The most common location uterine in 46%. 52,11% (37 patients) exhibited metastatic onset. 64% had pulmonary involvement, predominantly followed by peritoneal localization. Survival in patients with non-metastatic onset, was 58 months (range: 51-64 months), compared to 24 months for metastatic onset (range: 13-34 months), p-value of 0.003. PFSl in different treatment lines: Doxorubicin (D): 8 months, Doxorubicin + dacarbazine(D+DTIC): 12 months, Doxorubicin+trabectedin(D+tra): 9 months, Epirubicin + ifosfamide (Epi+Ifo): 7 month, gemcitabine + docetaxel (Gem+Doc): 7 months and Doxorubicin + olaratumab (D+olara): 7 months, p=0,07. Overall survival (OS) D: 47 months, D+DTIC: 74 months, D+tra 42 month, Epi+Ifo: 30 months, Gem+Doc: 37 months and D+olara: 34 months. Limitation of retrospective assessment. Slight increase in progression-free survival comparing with the literature. Epi+Ifo should not be a standard option in leiomyosarcoma, as literature data show a low response and limited disease control. However, in our historical series, it was a chosen line in 7 patients. OS, the combination of D+DTIC stands out, doubling overall survival compared to historical data. 86% reach second lines. Assessing PFS2 in treatment, a notable survival of 9 months with tra stands out, surpassing the average and comparing with the trabectedin second-line study showing a PFS of 4.2 months.

Line (geometry)

10.1016/j.esmoop.2024.102466

Cite

Citations (0)

1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study

Annals of Oncology (2021)

Luís Paz-Ares Edurne Arriola M.R. García Campelo María Pilar Diz Taín M.C. Marti Blanco

Durvalumab

10.1016/j.annonc.2021.08.251

Cite

Citations (2)

53P Oral metronomic-continuous cyclophosphamide (MCy) for elderly or unfit patients with advanced soft tissue sarcoma (STS): Reina Sofía University Hospital experience

ESMO Open (2023)

A.L. Moreno Vega L. Navarro Berlanga R. Plaza Borrego M.T. Caro Cuenca M.A. Gomez España

10.1016/j.esmoop.2023.101090

Cite

Citations (0)

142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab

Annals of Oncology (2022)

Dolores Isla Edurne Arriola M.R. García Campelo C. Martí P. Diz Taín

Durvalumab

Carboplatin

10.1016/j.annonc.2022.02.173

Cite

Citations (2)

1745P How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center

Annals of Oncology (2024)

Sebastián Díaz L. Fernández G. Martínez Bernal Irene Carrasco García Inmaculada del Rincón

Trabectedin

10.1016/j.annonc.2024.08.1837

Cite

Citations (0)

1797P Association between baseline PD-L1 expression in circulating leukocytes, the presence of immune-related adverse events (irAEs) and survival outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC) from the CANTABRICO trial

Annals of Oncology (2024)

A. Piedra Albert Guinart-Cuadra Maria Mulet Carlos Zamora Jose Alejandre

10.1016/j.annonc.2024.08.1888

Cite

Citations (0)

125P Trabectedin as second line: Data of a high-volume center around the last 5 years

ESMO Open (2024)

Sebastián Díaz G. Martínez Bernal L. Fernández Irene Carrasco García A.L. Moreno Vega

Approximately 20% of patients at diagnosis, and about 30–40% of patients with an initial diagnosis of localized sarcoma will develop distant metastasis and will eventually succumb to the disease. Available therapeutic lines for soft tissue sarcomas are diverse, each offering a set of specific characteristics. Beyond first-line, disease control is modest, with median progression-free survival (PFS) ranging 2.6–4.6 months. In this case, the value of trabectedin has been emphasized beyond the first line in the treatment of metastatic soft tissue sarcomas. Trabectedin is a marine-derived alkaloid, approved for the treatment of advanced STS after anthracyclines and ifosfamide. Retrospective review of the medical records of patients who have received trabectedin in the last 5 years. A descriptive analysis has been conducted on the age at presentation, histological subtype, initial onset, and the chemotherapy line in which trabectedin was administered. In a subsequent step, the PFS and overall survival (OS) of the treated patients were analyzed. Additionally, a specific analysis was conducted on the subgroup that received a combination with radiotherapy. We included 207 patients (p). 116p women (56%). The median age 56 years. The most common metastatic site are lungs (68,6%). The most common subtypes were leiomyosarcoma (Lei) 38,2%, liposarcoma (L) 21,3%, Undifferentiated Pleomorphic Sarcoma (UPS) 10,1%, sinovial sarcoma (SiS) 6,8% and stromal sarcomas (StS) 4,3%. 73 p get treatment at second line, and 75 p get trabectedin in third line. PFS in all p is around 6 months influenced due to time p get treatment. PFS in p treated at 2° line 14 month, 6 month as 3° line, and lower in subsequences lines. p = 0,001. The different is also observed in OS. The different subtypes presented with different PFS, 10 month in ESF, 9 month in L, 8 month in Lei, 8 months in StS and 3 moths in UPS. All patients treated showed benefit with PFS 6 month, higher than literature review. However, there are significance different with a higher PFS in patient with lower number of previous lines. There are some histotype with higher benefit L, leiomyosarcoma an synovial sarcoma. Trabectedin is a useful second line, with benefit in all subtypes, showing a high disease control over 4 month.

Trabectedin

Center (category theory)

Line (geometry)

10.1016/j.esmoop.2024.102514

Cite

Citations (0)